MicroRNAs regulate diverse cellular processes and play an integral role in cancer pathogenesis. Genomic variation within miRNA target sites may therefore be important sources for genetic differences in cancer risk. To investigate this possibility, we mapped HapMap single nucleotide polymorphisms (SNP) to putative miRNA recognition sites within genes dysregulated in estrogen receptor-stratified breast tumors and used local linkage disequilibirum patterns to identify high-ranking SNPs in the Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer genome-wide association study for further testing. Two SNPs, rs1970801 and rs11097457, scoring in the top 100 from the CGEMS study, were in strong linkage disequilibrium with rs1434536, an SNP that resides within a miR-125b target site in the 3 ¶ untranslated region of the bone morphogenic receptor type 1B (BMPR1B) gene encoding a transmembrane serine/threonine kinase. We validated the CGEMS association findings for rs1970801 in an independent cohort of admixture-corrected cases identified from families with multiple case histories. Subsequent association testing of rs1434536 for these cases and CGEMS controls with imputed genotypes supported the association. Furthermore, luciferase reporter assays and overexpression of miR-125b-mimics combined with quantitative reverse transcription-PCR showed that BMPR1B transcript is a direct target of miR-125b and that miR-125b differentially regulates the C and T alleles of rs1434536. These results suggest that allele-specific regulation of BMPR1B by miR-125b explains the observed disease risk. Our approach is general and can help identify and explain the mechanisms behind disease association for alleles that affect miRNA regulation. [Cancer Res 2009;69(18):7459-65] 
Introduction
MicroRNAs (miRNA) are a recently discovered class of short noncoding RNA genes that act posttranscriptionally as negative regulators of gene expression and play fundamental roles in cell growth, apoptosis, hematopoietic lineage differentiation, and differentiation (1, 2) . Functional studies indicate that changes in miRNA expression patterns might underlie human pathologies, including malignancies (3, 4) . In addition, variations in miRNA target sites mediated by single nucleotide polymorphisms (SNP) may be associated with human cancers (5, 6) .
Gene expression profiling studies have identified specific signatures for breast cancer and are used to guide patient treatment with both the Oncotype Dx and Mammaprint tests in use clinically (7, 8) . We previously described a meta-analysis of multiple independent breast cancer RNA expression studies whereby a unified set of dysregulated genes was identified in estrogen receptor (ER)+ and ERÀ tumors. The identification of germline variations in elements controlling RNA expression (i.e., transcription factor or miRNA recognition sites) may provide clues as to the mechanistic basis for the observed variations in gene expression patterns.
Genome-wide association studies (GWAS) have been used in many common diseases to identify SNPs associated with disease (9, 10) . To date, four independent studies examining breast cancer patients have identified multiple SNPs associated with disease (10) (11) (12) (13) . Although some association signals seem universal in multiple studies (i.e., several SNPs within FGFR2), often these studies also yield vastly differing collections of SNPs associated with disease perhaps owing to differences in study design. Although many disease-associated SNPs are nongenic, and thus their contribution to disease pathogenesis is unclear, many are likely to reside in gene regulatory elements that may influence gene expression patterns observed in tumors.
We describe an integrative genomic approach leveraging gene expression patterns, miRNA targeting, breast cancer GWAS data, and biological testing to identify a disease-associated SNP in the 3 ¶ untranslated region (UTR) of BMPR1B gene. To identify this SNP, we mapped a set of reference SNPs from the HapMap project to prospective miRNA target sites located in the 3 ¶UTRs of a previously identified set of dysregulated ER+ and ERÀ genes (14) . An analysis of local linkage disequilibrium (LD) patterns surrounding these SNPs identified one SNP (rs1434536) in strong LD with two SNPs showing a high degree of association in the Cancer Genetic Markers of Susceptibility (CGEMS) study. We replicated this association in an independent set of cases identified from families with multiple case histories and common CGEMS controls after controlling for population stratification with ancestry informative markers (AIM). We provide strong support that allelic variation at rs1434536 influences interactions with miR-125b leading to differences in BMPR1B expression levels. The approach described is generally applicable and provides clues to the role cisacting allelic variation plays in tumor gene expression patterns via interactions with the miRNA machinery in disease pathogenesis.
Materials and Methods
Mapping SNPs to miRNA targets. Our input data consisted of 275 candidate genes previously identified as constituting the top 1% of genes dysregulated in ER+ and ERÀ (130 and 145 genes, respectively) breast cancer tumors (14) and their annotated 3 ¶UTR sequences from the University of California at Santa Cruz Table Browser (National Center for Biotechnology Information Build 36.1), mature human miRNA sequences from miRBase 16 , and SNPs from HapMap. 17 Using custom python scripts, we (a) identified all unique 7mer seeds (nucleotides 2-8) within the mature miRNA sequences, (b) identified all seed sites-that is, locations with perfect reverse complementarity to a 7mer seed-within the candidate genes' 3 ¶UTRs, (c) identified all HapMap SNPs that mapped to one of the seed site locations, and (d) removed all SNPs that had no reported minor allele in any HapMap population.
Description of study populations. Four hundred fifty-nine probands from a breast cancer-affected sibling pair cohort were recruited from a multi-institutional study [Eastern Cooperative Oncology Group (ECOG) Cancer in Sibling Study, E1Y97] under protocols approved by the respective Institutional Review Boards at each institution. The mean age of diagnosis for probands was 55 y (range, 16-87 y) and disease status was verified by pathology reports for 96.5% of cases (443 of 459; Supplementary Materials and Methods). We collected self-reported ethnicity data for both maternal and paternal grandparents from 78% (356) of our cases. CGEMS patients consisted of 1,142 controls and 1,145 cases of postmenopausal breast cancer and were gathered from the Nurses Health Study as described previously (10, 15) . Self-reported ethnicity information was unavailable for these individuals.
Genotyping and quality control. DNA samples were prepared as previously described from peripheral leukocytes (16) . SNP genotyping was performed using Sequenom MassARRAY genotyping technology and iPLEX chemistry according to manufacturer's instructions (17) . AIMs were developed into two multiplex assays (Supplementary Table S1 ) as defined by the 64 I n 4 AIMs described by Kosoy and colleagues (18) . Genotyping success ranged from 95.9% to 97.8% for the three association SNP in our cases. Patient samples were genotyped and samples demonstrating <80% completion rate (46 of 459) were subjected to a second round of genotyping. Quality control metrics for our cases included a minimum of 80% genotyping success, whereas SNPs with completion rates <90% were discarded. After two rounds of genotyping, four cases and nine AIMs were discarded from further analysis, having not met quality control metrics.
Population structure analysis and association testing. For admixture analysis, we used 45 AIMs and combined our cases (455), the CGEMS controls (1, 142) and seeded the analysis with a training set of 270 HapMap reference samples (CEU, YRI, and CHB+JTP) to perform STRUCTURE analysis with k = 3 populations (Supplementary Fig. S1 ). We observed general agreement between our patient's self-reported ethnicity and genetic ancestry as determined by our AIMs, although rarely a patient's self-identified ancestry was at odds with the calculated CEU ancestral component. In these instances, we relied on STRUCTURE results to determine genetic ancestry. For association testing, each SNP was analyzed using a logistic regression model where odds ratios (OR) are estimated for homozygous and heterozygous states of the indicated cases and CGEMS controls. For the causative SNP rs1434536, we directly genotyped our cases and imputed genotypes from CGEMS controls using HapMap CEU reference individuals (Supplementary Materials and Methods). IMPUTE and SNPTEST were used for genotype determination and association testing of rs1434536 as described (19) .
Cell lines, cloning, and dual luciferase reporter assays. Cell lines were maintained in F12/DMEM, respectively, supplemented with 10% fetal bovine serum, and 1% Pen/Strep. Luciferase reporter targets were generated for the miR-125b target region of BMPR1B by cloning PCR products from HapMap NA18505 (rs1434536-C/T) into the 3 ¶-UTR of the Renilla luciferase gene in the psiCheck2.2 dual reporter vector (Promega). Clones containing T or the C alleles at rs1434536 were verified by ABI fluorescent dideoxy sequencing and transiently transfected into MCF-7 and MD-MBA-231 cell lines. Renilla luciferase (hRluc) activity was measured 48 h after transfection. Cells were lysed with 120 AL Passive Lysis Buffer (Promega), and luciferase levels were analyzed from 10 AL lysates using the dual luciferase reporter assay (50 AL of each substrate reagent; Promega) on a Veritas Microplate Luminometer (Turner Biosystems). Changes in expression of Renilla luciferase (target) were normalized relative to Firefly luciferase.
Transfection of miR-125b duplexes and qRT-PCR of BMPR1B. siRNAs (IDT) were transfected into MCF-7 or MDA-MB-231 cells using RNAiMax (Invitrogen) using the manufacturers recommendations. Twentyfive pmol of each strand of the siRNA target were annealed by heating to 94jC for 2 min to form duplexes in buffer supplied by the manufacturer then allowed to cool to room temperature. Transfection efficiencies were monitored by transfecting in parallel a Cy3-labeled DS scrambled control siRNA duplex (IDT). Cells were harvested 24 h after transfection and RNAs were purified. cDNA was synthesized from 25 ng RNA using random hexamers and M-MLV reverse transcriptase, and was subsequently amplified with BMPR1B specific primers (Supplementary Materials and Methods). We calculated the SQ values and normalized BMPR1B transcript to GAPDH. RNA quantitation experiments were performed in triplicate from two independent transfection experiments.
Results
Multiple HapMap SNPs map to putative miRNA target sites in ER+ and ERÀ dysregulated genes. Because allelic variations in miRNA binding sites have been shown to influence transcript levels (20), we examined if commonly occurring SNPs present in miRNA binding sites could be identified from the HapMap Consortium. Using a previously described set of genes dysregulated in ER+ and ERÀ breast tumors (14), we identified all HapMap SNPs residing within putative miRNA target sites in the genes' 3 ¶UTRs (see Materials and Methods). We focused our search on the miRNA seed region, as the seed nucleates the miRNA to the complementary mRNA target region and is the main determinant for miRNA targeting (21) . More specifically, we based our miRNA target site predictions on 7mer seed sites as we expected these would give an acceptable tradeoff between the number of false-negative and false-positive predictions (21) . Our search identified 63 unique SNPs. Thirty-seven and 26 SNPs mapped to genes dysregulated in ER+ and ERÀ tumors, respectively (Supplementary Table S2 ). This collection of SNPs was considered for further analysis.
A miR-125b target site SNP in BMPR1B is in strong LD with breast cancer-associated SNPs. To prioritize the 63 SNPs for further biological testing, we mapped each to the publicly available CGEMS breast cancer GWAS 18 data set looking for SNPs that had signals of association. However, only seven mapped directly to this data set-none of which showed a statistically significant association. Twenty of the 63 target SNPs were either monomorphic (14 SNPs) in CEU samples or exhibited minor allele frequencies of <0.05 (6 SNPs) and were therefore not expected to be represented on the GWAS array, as rare SNPs (typically <5% minor allele frequency in CEU samples) are often excluded from these arrays. Moreover, the arrays typically contain only subsets of SNPs within haplotype blocks, but these SNPs can be used as proxies for the missing SNPs within blocks. To prioritize the remaining 43 SNPs, we therefore first used local LD structure from HapMap to identify proxy SNPs in the CGEMS data set and second observed such proxies' genome-wide association rank in the CGEMS set.
One SNP, rs1434536, showed high LD to rs1970801 and rs11097457 (r 2 = 0.81) in the HapMap CEU reference samples (Fig. 1 ). rs1970801 and rs11097457 ranked 79th and 67th in the CGEMS GWAS association data (P = 0.00017 and P = 0.00014, respectively, unadjusted score test). These SNPs exhibit extensive pairwise LD (r 2 = 0.93) in the CEU HapMap reference samples. We conclude that they likely represent the same association signal. The target site SNP rs1434536 lies 5.4 kb downstream of rs1970801 and 0.85 kb upstream of rs11097457 in the 3 ¶UTR of the Bone Morphogenetic Protein Receptor 1B (BMPR1B) gene. The SNP's C!T change alters a 7mer seed site for miR-125b to a 6mer site-a change expected to reduce miR-125b's binding affinity to the site (Fig. 2) . Moreover, miR-125b is differentially expressed in normal versus breast cancer in general, and in ER+ versus ERÀ tumors in particular (22) (23) (24) . The combined observations that miR-125b and BMPR1B are differentially expressed in breast cancer, that allelic variation of rs1434536 likely disrupts miR-125b's regulation of BMPR1B, and that the SNP is in LD with two breast cancerassociated SNPs, suggest that rs1434536 has a pathogenic role in breast cancer.
Independent cohort confirms the association of BMPR1B SNP with breast cancer. Although the CGEMS results did not reach genome-wide significance for either rs1970801 or rs11097457, we elected to replicate the CGEMS results by screening rs1970801 in an independent cohort of genetically enriched breast cancer cases. In parallel, we screened two additional SNPs for association with disease: rs1219648 and rs6831418, which ranked 2 and 52, respectively, in the unadjusted CGEMS genomewide rankings (Supplementary Table S3 ). SNP rs6831418 resides within an intron of BMPR1B , f320 kb upstream of rs1970801 (r 2 = 0.118 with rs1970801), and a regional association plot of the CGEMS data (Fig. 1A ) also indicated potential disease association. SNP rs1219648, present in intron 2 of FGFR2, was previously shown to be the most strongly associated SNP with breast cancer in multiple GWAS studies including the CGEMS, Wellcome Trust (rs2981582, Figure 1 . Regional CGEMS association data and LD structure in BMPR1B region. A, localized association data for CGEMS breast cancer data set (Chr 4, 95.3-96.8 Mb). Transcripts from the RefSeq database are shown in the top third part of the graph; black, selected SNPs. B, LD structure of BMPR1B (NM_001203) 3 ¶UTR region. An f19-kb interval of the BMPR1B gene (black boxes and white arrow-box, coding sequence and 3 ¶ UTR exons) and the surrounding region is depicted with select SNPs shown across the top. rs1434536 (solid box ), located in 3 ¶UTR of BMPR1B, is flanked by rs1970801 centromerically and rs11097457 telomerically (dashed boxes ). Shaded boxes, pairwise LD values measured as r 2 with values listed; black boxes, perfect correlations (r 2 = 1). The direction of BMPR1B transcription, relative to the genome assembly, is from left to right. Panel adapted from Haploview (http://www.broad.mit.edu/mpg/haploview/). C, haplotype structure of three selected SNPs (boxed in B ) with frequencies from HapMap CEU population where rs1970801 has been converted to + strand of University of California at Santa Cruz assembly. r 2 = 1.0 with rs1219648), and Memorial Sloan-Kettering Cancer Center Ashkenazi Jewish (rs1078806, r 2 = 0.96 with rs1219648) studies (10, 11, 13) . We used rs1219648/FGFR2 as a positive control for association in our cases, as the three previous studies indicated this SNP is a universal marker for disease. Our breast cancer cases consisted of probands ascertained by virtue of a living, affected full sibling with disease, whereas we used admixture-corrected, shared disease-free controls from the CGEMS study. The use of cases ascertained by virtue of family history served to enrich for alleles with a strong genetic etiology. In addition, the use of shared controls has recently been described for multiple common disease scenarios (9, 25, 26) .
Before comparing allele frequencies between our cases and CGEMS controls for the three SNPs, we sought to eliminate two potential biases: population differences between cases and controls and technical artifacts (e.g., errors in genotype scoring). To reduce the likelihood that any observed associations could be mediated by differences in the genetic ancestry of our cases and the controls, we elected to use AIMs and only analyze cases and controls with a high percentage (>90%) of Caucasian ancestry as defined by HapMap CEU reference samples. Recently, AIMs useful for determining intercontinental admixture have been described to facilitate structured association testing in case-control studies (27) . We selected 59 AIMs (Supplementary Table S2 ) based on the 64 most informative I n 4 markers as described by Kosoy and colleagues (18) for population structure analysis. These markers have a high discriminatory power to distinguish CEU, YRI, CHB+JPT, and AMI (American Indian) continental populations. After STRUCTURE analysis (Supplementary Materials and Methods), we observed 94.1% (428 of 455) of our cases exhibited >90% CEU ancestry, whereas CGEMS controls showed 93.3% (1,064 of 1,142) CEU ancestry ( Supplementary Fig. S1 ). Predicted effect of allelic variation at rs1434536 on miR-125b recognition. Top, BMPR1B gene as described in Fig. 1 (white box, 3 ¶UTR) . Bottom, partial sequence of BMPR1B 3 ¶UTR and SNP rs1434536 (boxed). Bottom, seed pairing of miR125-b (nucleotides 2-8 at 5 ¶ end) with C (top sequence ) and T(U) (bottom sequence) alleles of rs1434536. NOTE: Association testing with ECOG breast cancer cases (n = 428) and common CGEMS controls (n = 1064), which have been corrected for genetic admixture with ancestry informative markers (see Materials and Methods). *Unadjusted P value from the score test with degrees of freedom (df) of 2 in logistic regression. cGenotypes in CGEMS controls imputed by IMPUTE. bScore test with df of 2 (performed by SNPTEST) and considering imputation uncertainty.
We next used logistic regression and calculated ORs testing independently for both heterozygotes and homozygotes carrier states omitting both ECOG cases and CGEMS controls not exhibiting >90% CEU class membership (Table 1) . rs1219648/ FGFR2 showed association in the ECOG cases exhibiting a heterozygote and homozygote OR of 1.29 and 1.72 (P = 0.0052) for the minor allele (G). These ORs are similar to those observed for the original CGEMS findings of 1.25 and 1.81 for heterozygotes and homozygotes. rs1970801-T also exhibited association in the ECOG cases with an OR of 1.24 and 1.84 for heterozygotes and homozygotes (P = 0.00048). These ORs are comparable with those previously observed in the CGEMS study (1.21 for T/G and 1.65 for T/T). In contrast, rs6831418 did not exhibit significant association (P = 0.177) in our cases. One explanation for the lack of confirmatory association with rs6831418 may stem from departure from Hardy Weinberg equilibrium (HWE) in both CGEMS cases and controls, whereas all three SNPs were in HWE for our ECOG cases (Supplementary Table S3 ). As final verification of association, we genotyped rs1434536 in our cases and, using the CEU HapMap LD structure, imputed genotypes for rs1434536 in admixturecorrected CGEMS controls. We observed association in our cases with an OR of 1.29 for T/C heterozygotes and an OR of 1.94 for major allele homozygote T/T (Table 1) . Based on the replication of association in our breast cancer cases for rs1219648/FGFR2, rs1970801-T and rs1434536-T we concluded that rs1434536 was indeed associated with disease risk.
miR-125b differentially regulates the allelic variants of rs1434536. Next, we tested a biological model where miR-125b differentially regulates the C/T allelic variants of rs1434536 in BMPR1B. In this model, rs1434536-T results in increased BMPR1B transcript levels, which gives an increased breast cancer risk as shown by the association testing. Computational models of miRNA target interactions predicted that miR-125b would down-regulate the C allele more strongly than the T allele, as the T allele forms a weaker 6mer seed site for miR-125b binding ( Fig. 2; ref. 21) . The PITA thermodynamic model of miRNA binding supports this allelic difference. The algorithm models miRNA targeting as a competition between the free energy gained by miRNA binding and the energetic cost of displacing existing RNA secondary structure at the target site (28) . PITA summarizes this model in the DDG score, where smaller values indicate stronger miRNA binding. Inputting the 200 nucleotides centered on rs1434536-C/T alleles to PITA gave DDG values of À0.53 and 3.09, which suggested reduced binding of miR-125b to BMPR1B for the T allele.
To test our model, we cloned partial BMPR1B 3 ¶UTR fragments from a rs1434536 heterozygote into the luciferase 3 ¶UTR reporter vector psiCHECK-2 to compare the luciferase activities between the two alleles at rs1434536. Vectors containing either C or T alleles were transiently transfected into ER+ and ERÀ cell lines and Renilla luciferase activity was measured. When transfected into MCF-7 (ER+) cells the C-allele gave a 38% reduced luciferase activity relative to the T allele consistent with our model (Fig. 3B) . However, when we tested luciferase activity in MD-MBA-231 (ERÀ) cells, we observed no difference between the C and T alleles. Additionally, the overall luciferase activities observed were lower in MDA-MB-231 cells relative to MCF-7 cells, which may reflect the higher levels of miR-125b in this cell line (22) .
As an additional test of our model, we transiently transfected synthetic miR-125b oligos into MCF-7 and MDA-MB-231 cells, and quantitated endogenous BMPR1B transcript levels by qRT-PCR. Prior genotyping MCF-7 and MDA-MB-231 cells revealed homozygous T and C genotypes at rs1434536, respectively. The oligonucleotides, which mimicked the annotated hsa-miR125b:hsa-miR-125b-1* duplex, only weakly down-regulated BMPR1B in MCF-7 (Fig. 3C) , which is consistent with our model. In contrast, transfection with a miRNA mimic (siR), not targeting the miR-125b site, resulted in an 80% reduction in BMPR1B transcript levels. When we tested these duplexes in MDA-MB-231 cells, BMPR1B levels were <1/50 of the levels in MCF-7 and below the assay's detection limit (data not shown). The low levels of BMPR1B levels in ERÀ MDA-MB-231 cells were consistent with our prior meta-analysis from ER+ and ERÀ tumors and with increased levels of endogenous miR-125b in 231 cells (22) .
Discussion
Both rs1434536-T and rs1970801-T were shown to be associated with increased risk in an independent cohort of admixturecorrected cases and controls. We have shown that miR-125b negatively regulates BMPR1B and that C/T allelic variation (rs1434536) within the target site disrupts the regulation of miR125b. The presence of rs1434536-T leads to loss of miR-125b regulation, increased BMPR1B expression, and ultimately elevated disease risk. Consistent with this, increased BMPRIB expression is associated with high tumor grade, proliferation, cytogenetic instability, and a poor prognosis in ER+ breast carcinomas (29) . Moreover, breast cancers in general and ER+ tumors in particular Figure 3 . Allelic variation of rs1434536 influences luciferase reporter activity and miR-125b targeting. A, structure of luc allelic reporter constructs depicting psiCheck-2.2 (Promega) dual luciferase reporter constructs. B, luciferase reporter assays to measure C!T allele differences at rs1434536. Cells were transiently transfected with C-or T-bearing reporters into MCF-7 or MDA-MB-213 cells, which is predicted to influence the recognition of the miR-125b seed sequence in the BMPR1B 3 ¶UTR. After 48 h, Renilla luciferase (hRluc) activity was measured and normalized to Firefly luciferase. Results are shown as percentage relative to luciferase activity. Data are from four independent transfection experiments with assays performed in triplicate (n = 4). *, P < 0.05; **, P > 0.05. C , miR-125b weakly down-regulates BMPR1B . MCF-7 cells were transfected with siRNA duplexes and RNAs were harvested 24 h after transfection. cDNA was synthesized and used for real-time qRT-PCR analysis of BMPR1B expression normalized to a GAPDH standard. CY3, scrambled negative control siRNA; siR, siRNA duplex targeting position 867 in BRPR1B ; miR-125b, duplex mimicking hsa-miR-125b and targeting the C allele at rs1434536. Expression levels are relative to the CY3 control (n = 3).
seem to have reduced levels of miR-125b (22) (23) (24) , which in light of these results, at least partly explain why ER+ tumors have increased BMPR1B expression (14) .
BMPR1B binds bone morphogenetic proteins (BMP) and are multifunctional signaling molecules that belong to the transforming growth factor h superfamily and were first identified based on their ability to form bone at extraskeletal sites (30) . Once activated, BMP/receptor complexes phosphorylate cytosolic SMAD proteins that translocate to nucleus and regulate target genes (31). Our findings indicate that ER+ patients harboring elevated BMPR1B transcript levels may have poorer outcomes when carrying the risk-associated rs1434536-T allele. Whereas not only identifying a new target for further study, these results show the importance of combining tumor expression profiles and genotype data in determining a patients' clinical prognosis.
More generally, our methodology has identified a set of allelic variants present in miRNA recognition sites within a set of dysregulated ER responsive genes. Independent of our efforts, Adams and colleagues (20) identified rs9341070 in a miR-206 site in the ESR 3 ¶UTR. Allelic variation at this SNP was shown to influence ESR expression over 3-fold in HeLa cells. This SNP resides in a domain upstream of the miRNA seed targeting sequence (nucleotides 2-8), yet we identified this same SNP by virtue of its presence in a miR-122 seed region (Supplementary Table S1 ). However, due to the low frequency of rs9341070 in CEU samples (<0.01) this SNP is not represented in any GWAS array. This illustrates a common deficiency of GWAS data sets: the absence of low frequency/rare SNPs that may also play a role in disease risk (32) . One would anticipate that appropriately powered future association studies of these potential miRNA interacting rare variants may support their role in risk.
We found that T/T homozygotes at rs1970801 had slightly higher ORs in our ECOG cases (1.84) compared with the CGEMS cases (1.65), and this could be explained by differences in case ascertainment. CGEMS cases were recruited from a prospective cohort study where only 22% (274 of 1,145) reported first-degree family history as opposed to our cases whereby all cases exhibited first-degree family history, namely an affected sibling. Second, all CGEMS cases were of postmenopausal disease, whereas only half of the ECOG cases indicated an age of diagnosis of <50. These differences indicate that the genetic contribution to risk may have been underestimated for rs1970801-T in the CGEMS study reinforcing the importance of family history in confirmatory replication studies as this may be valuable for later risk-assessment predictions. We observed a higher OR for TT homozygotes at rs1434536 when we tested for association with imputed genotypes in the CGEMS controls compared with rs1970801 TT homozygotes (1.94 versus 1.84; Table 1 ). These results also highlight both the merits of the tagging SNPs used in the GWAS studies and the utility of imputation for deriving missing genotypes.
Our replication of prior disease associations for two SNPs (Table 1) relied on using a set of AIMs to correct for differences in genetic admixture between our cases and CGEMS controls. Approximately 6% to 7% of CGEMS controls and CGEMS cases (data not shown) showed <90% CEU ancestry as defined by HapMap reference samples. This indicates that population substructure introduced by intercontinental admixture may have contributed to potential false positives or missed associations in the original CGEMS data. To rectify this, it has been proposed that AIM panels should be used before GWA tests (26) . More subtle levels of admixture within both European and Chinese populations have recently been described, which will necessitate the continued use of extended AIM panels to discern finer levels of population substructure as a prelude to association testing and biological testing (33) (34) (35) .
The usefulness of GWAS data for identifying breast cancer susceptibility alleles is premised on the common disease-common variant hypothesis whereby SNPs (>5% frequency) may act as surrogates to identify causal variants. Replication studies of the very top tier signals in breast cancer have firmly established some associations; however, modest signals in first round GWAS screens may not be selected for rescreening (36) . Thus, we feel it is likely that future meta-analyses of multiple GWAS data sets will provide additional candidates for examination (37) .
These findings have implicated a germline variant in breast cancer susceptibility and provided a strong model for biological causality via miRNAs. Our approach relies on integrating association data, expression profiles, and testable biological models to evaluate potential disease alleles in pathogenesis (38) . As GWAS have identified only common SNPs as genetic risk factors, it is likely that many rare alleles present within motifs for miRNAs and additional trans-acting regulators (i.e., transcription factors) remain to be identified. In addition, approaches such as whole genome sequencing and the identification of common recurrent somatic mutations in breast tumors may provide a large collection of potential disease alleles for exploration (39, 40) .
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